Related Experiment Video

Updated: Jan 22, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

877

PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Alia Ghoneum1, Neveen Said2

  • 1Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.

Cancers
|July 10, 2019
PubMed

Insights

Ovarian cancer, a lethal malignancy, often involves mutated phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways. This review explores their interconnection in ovarian cancer progression.

Area of Science:

  • Gynecologic Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Ovarian cancer is a leading cause of cancer death in the United States.
  • The phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in ovarian cancer.
  • The nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathway is also implicated in ovarian cancer pathogenesis.

Purpose of the Study:

  • To review the role of the PI3K/AKT/mTOR pathway in ovarian cancer.
  • To investigate the interconnection between the PI3K/AKT/mTOR and NFκB pathways in ovarian cancer.
  • To understand the association of these pathways with advanced disease and poor prognosis.

Main Methods:

  • Literature review of recent studies on PI3K/AKT/mTOR and NFκB pathways in ovarian cancer.
  • Analysis of mutation and hyper-activation data for these pathways in ovarian cancer patients.
  • Examination of the relationship between pathway activation, disease grade, stage, and prognosis.

Main Results:

  • The PI3K/AKT/mTOR pathway is highly mutated and/or hyper-activated in a significant proportion of ovarian cancer cases.
  • The NFκB pathway also shows frequent alterations in ovarian cancer.
  • Dysregulation of both pathways is associated with advanced stage, high grade, and poor patient outcomes.

Conclusions:

  • The PI3K/AKT/mTOR and NFκB pathways represent critical signaling networks in ovarian cancer.
  • Understanding the interplay between these pathways is crucial for developing targeted therapies.
  • Targeting these interconnected pathways may offer new therapeutic strategies for ovarian cancer patients.
Keywords:
NFκBPI3K-AKT-mTORovarian cancertherapy

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
C4 Pathway and CAM01:27

C4 Pathway and CAM

Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
48.9K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.6K